Generic Name and Formulations:
Parathyroid hormone (recombinant) 25mcg, 50mcg, 75mcg, 100mcg; lyophilized pwd for SC inj after reconstitution.
Shire US, Inc.
Indications for NATPARA:
Adjunct to calcium and vitamin D to control hypocalcemia in hypoparathyroidism.
Limitations Of use:
Use only for patients uncontrolled on calcium supplements and active vitamin D alone. Not studied in hypoparathyroidism caused by calcium-sensing receptor mutations or in acute post-surgical hypoparathyroidism.
Individualize based on total serum calcium (albumin-corrected) and 24hr urinary calcium excretion. Give as SC inj in the thigh (alternate thigh daily). Initially 50mcg once daily; may increase in increments of 25mcg every 4 weeks up to max 100mcg daily, if serum calcium is not maintained >8mg/dL. May decrease to 25mcg daily if serum calcium repeatedly >9mg/dL. If currently receiving active vitamin D: decrease vitamin D dose by 50% if serum calcium >7.5mg/dL. Maintenance: use lowest dose to achieve total serum calcium within the lower half of the normal range (approx. 8–9mg/dL). See full labeling.
<18yrs: not established.
Confirm sufficient 25-hydroxyvitamin D stores and serum calcium >7.5mg/dL prior to initiation. Avoid in those with increased baseline risk of osteosarcoma (eg, Paget's disease of bone, unexplained elevations of alkaline phosphatase, pediatric and young adults with open epiphyses, hereditary disorders predisposing to osteosarcoma, history of external beam or implant radiation therapy involving the skeleton). Measure calcium concentration every 3–7 days after starting therapy and when adjusting Natpara, active vitamin D, or calcium supplement doses; consider holding and/or reducing dose if severe hypercalcemia occurs. Renal impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant alendronate: not recommended. Concomitant digoxin: monitor serum calcium and digoxin levels and for digitalis toxicity; adjustments may be needed for both drugs.
Paresthesia, hypocalcemia, headache, hypercalcemia, nausea, hypoaesthesia, diarrhea, vomiting, arthralgia, hypercalciuria, pain in extremity; possibly osteosarcoma.
Multi-dose cartridges (dual-chamber)—2
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|